The main predictive biomarkers that stratify patients for immunotherapy, including PD-L1 and PD-1 expression, tumor mutation burden, tumor-infiltrating lymphocytes, and immune gene signature, are under investigations in meningiomas [45]. The gene discussed is CD274; the disease is neoplasm.